<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414020</url>
  </required_header>
  <id_info>
    <org_study_id>623-4/2020</org_study_id>
    <nct_id>NCT04414020</nct_id>
  </id_info>
  <brief_title>Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors</brief_title>
  <official_title>Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuronal injury is evident in elective craniotomy for space occupying lesions. Surgical
      trauma and mechanichal impact of the tumor causes neuronal injury. Neurosreroid progesterone
      is a neurotransmittern , trail to use in abolishing neurotoxcicty
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progesterone is a natural neurosteroid that we are trying to use to impede both direct
      neuronal injury cauesd by and indirectly by surgical trauma. Progesterone can decreas
      vasogenic brain oedema. Our primary outcome is to ameliorate microscopic cytoplasmic injury
      and decrease brain oedema exploited by biopsy from brain tumor interface. Exclusion criteria
      demonstratd as refusal to participate in the trial , emergency craniotomy, recurrent brain
      tumor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With craniotomy-Related Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Degree of microscopic cellular injury and brain odema in brain biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with neuronal deficit</measure>
    <time_frame>2 months</time_frame>
    <description>Sensory, motor or autonomic dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Diffuse Traumatic Cerebral Edema</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group receiving conventional treatment without progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesteron</intervention_name>
    <description>intramusculer progesterone</description>
    <arm_group_label>progesterone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All elective brain tumors elligible for craniotomy

        Exclusion Criteria:

          -  Refusal to participare

          -  Emergency craniotomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mina Raouf, MD</last_name>
    <phone>01015752424</phone>
    <email>drmina2015@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Al MinyƒÅ</city>
        <state>Abohelal</state>
        <zip>6115</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mina raouf, MD</last_name>
      <phone>01015752424</phone>
      <email>Drmina2015@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>omaima mohammad, MD</last_name>
      <phone>01061762894</phone>
      <email>Omayamshehata@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Minya</city>
        <state>Abohelal</state>
        <zip>6115</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mina raouf, MD</last_name>
      <phone>01015752424</phone>
      <email>Drmina2015@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>omaima mohammad, MD</last_name>
      <phone>01061762894</phone>
      <email>Omayamshehata@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>May 30, 2020</last_update_submitted>
  <last_update_submitted_qc>May 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health and Population, Egypt</investigator_affiliation>
    <investigator_full_name>Mina Maher</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Progesterone</keyword>
  <keyword>brain tumor</keyword>
  <keyword>Neuronal biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

